Sheng-Bin Peng

2.8k citations

38 papers · 1.7k indexed · h-index 20

Impact in

Oncology top 5%
- Chemokine receptors and signaling
- Cancer-related Molecular Pathways
- Cytokine Signaling Pathways and Interactions
Immunology top 10%
- Immunotherapy and Immune Responses

Papers in

Oncology 26
- Chemokine receptors and signaling 9
- Colorectal Cancer Treatments and Studies 6
- Peptidase Inhibition and Analysis 4
- Cancer-related Molecular Pathways 4
Immunology and Allergy 3
- Cell Adhesion Molecules Research 3

Co-authors: Shuguang Huang Shuyu Li Donald C. Paul Sean G. Buchanan Vipin Yadav James J. Starling Youyan Zhang James R. Henry
Journals: Cancer Research (6 papers)Journal of Biological Chemistry (4 papers)Molecular Cancer Therapeutics (3 papers)Scientific Reports (2 papers)Journal of Clinical Oncology (2 papers)
Partner nations: United States Spain South Korea

In The Last Decade

Sheng-Bin Peng

37 papers receiving 1.6k citations

Peers

Countries citing papers authored by Sheng-Bin Peng

Since Specialization

Citations

This map shows the geographic impact of Sheng-Bin Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng-Bin Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng-Bin Peng more than expected).

Fields of papers citing papers by Sheng-Bin Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng-Bin Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng-Bin Peng. The network helps show where Sheng-Bin Peng may publish in the future.

Co-authors

The 25 scholars most cited alongside Sheng-Bin Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sheng-Bin Peng Line = papers co-authored together Sheng-Bin Peng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Parkinson disease–associated toxic exposures selectively up-regulate vesicular glutamate transporter vGlut2 in a model of human cortical neurons Molecular Biology of the Cell ·Hannah Lynn Holman, Juan M Seren, Wojciech Pasławski, マール企業価値研究グループ, Sheng-Bin Peng, Tracy L. Young‐Pearse, Per Svenningsson, Dennis J. Selkoe, Gary P. H. Ho	2025	0
2	Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas Proceedings of the National Academy of Sciences ·Laura Esteban-Burgos, Haiyun Wang, J.-H. Park, Jie Zheng, Carmen Blanco‐Aparicio, 趙東一, Gonzalo Goméz-López, Felicia Angeja Viator, Manuel Sanclemente, Carmen Guerra, Matthias Drosten, 向磊潘, Eduardo Caleiras, Jorge L. Martínez‐Torrecuadrada, Lluís Fajas, Sheng-Bin Peng, David Santamarı́a, Mónica Musteanu, Mariano Barbacid	2020	15
3	Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis Scientific Reports ·Jiangang Liu, Yong Beom Cho, Hye Kyung Hong, Song Wu, Philip J. Ebert, Steven M. Bray, Swee Seong Wong, Jason C. Ting, John Calley, Catherine F. Whittington, Shripad V. Bhagwat, Christoph Reinhard, Robert A. Wild, Do‐Hyun Nam, Amit Aggarwal, Woo Yong Lee, Sheng-Bin Peng	2020	23
4	Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors SHILAP Revista de lepidopterología ·Mark H. O’Hara, Wells A. Messersmith, Hedy L. Kindler, Chuan-hui Liu, Celine Pitou, Anna M. Szpurka, Dan Wang, Sheng-Bin Peng, Burkhard Vangerow, Anis A. Khan, Mythili Koneru, Andrea Wang‐Gillam	2020	37
5	Identifying metastasis-initiating miRNA-target regulations of colorectal cancer from expressional changes in primary tumors Scientific Reports ·Jongmin Lee, Hye Kyung Hong, Sheng-Bin Peng, Tae Won Kim, Woo Yong Lee, Shinya Masukawa, Hee Cheol Kim, Jiangang Liu, Philip J. Ebert, Amit Aggarwal, Sungwon Jung, Yong Beom Cho	2020	10
6	Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor ACS Medicinal Chemistry Letters ·Aruna Wijeratne, Junpeng Xiao, Yue Mei Li, Kelly Furness, Vera G M Sistenich, Mohammad Zia‐Ebrahimi, Ana Marta Hernández García, John Strelow, Robert D. Van Horn, Sheng-Bin Peng, David A. Barda, Thomas A. Engler, Michael J. Chalmers	2018	14
7	Abstract LB-185: Combination of an ERK1/2 inhibitor (LY3214996) with VEGFR-2 inhibitor enhances anti-tumor activity in KRAS mutant non-small cell lung cancer Cancer Research ·Wenjuan Wu, Shripad V. Bhagwat, Marjan Javanmard, Michelle L. Swearingen, Beverly L. Falcón, William T. McMillen, En-Ze Zhu, Sean G. Buchanan, Sheng-Bin Peng, Christoph Reinhard, Ramón V. Tiu	2018	1
8	Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120 Cancer Discovery ·Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn, Tinggui Yin, Sean G. Buchanan, Vipin Yadav, Igor Mochalkin, Swee Seong Wong, Yong Yue, Lysiane Huber, Ilaria Conti, James R. Henry, James J. Starling, Gregory D. Plowman, Sheng-Bin Peng	2016	117
9	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies PLoS ONE ·Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul, Lisa Kays, Ming Ye, Peter Vaillancourt, Michele Dowless, Louis F. Stancato, Julie Stewart, Mark Uhlik, Haiyan Long, Shaoyou Chu, Victor H. Obungu	2016	50
10	Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models Molecular Cancer Therapeutics ·Sheng-Bin Peng, Xiaoyi Zhang, Donald C. Paul, Lisa Kays, Wendy H. Gough, Julie Stewart, Mark Uhlik, Qi Chen, Yu‐Hua Hui, Maciej J. Zamek‐Gliszczynski, John A. Wijsman, Kelly M. Credille, Liang Yan	2014	116
11	The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation Molecular Cancer Therapeutics ·Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng	2014	104
12	Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets PLoS ONE ·Ying Chen, R.H. Collier, Xian‐Ming Chen, Thompson N. Doman, Xueqian Gong, Youyan Zhang, Tito Guterres da Cruz Boavida, Xiwen Ma, Richard E. Higgs, Shripad V. Bhagwat, Sean G. Buchanan, Sheng-Bin Peng, Kirk A. Staschke, Vipin Yadav, Yong Yue, Hosein Kouros‐Mehr	2014	108
13	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers Pharmacology & Therapeutics ·Vipin Yadav, Shih-Hsun Chen, Glenn J. Hanna, Sean G. Buchanan, Richard P. Beckmann, Sheng-Bin Peng	2014	26
14	Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data BMC Medical Genomics ·Jiangang Liu, Andrew Campen, Shuguang Huang, Sheng-Bin Peng, Xiang Ye, Mathew Palakal, A. Keith Dunker, Yuni Xia, Shuyu Li	2008	33
15	A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro Cancer Research ·Jonathan M. Yingling, Jianyong Shou, Xiaoling Xia, Yuefeng Chen, Lei Yan, W. Evans, Donald C. Paul, Raluca Botezatu, Rob Foreman, Robin L. Goode, K. M. Law, Sheng-Bin Peng, Mark Uhlik, James J. Starling	2006	1
16	Identification and expression of novel isoforms of human stromal cell-derived factor 1 Gene ·Yu Lan, Shivanee A P Kuhan, Sheng-Bin Peng, James Schrementi, S Kovacevic, Donald C. Paul, Eric Wen Su, Jian Wang	2006	170
17	Novel Lipoglycopeptides as Inhibitors of Bacterial Signal Peptidase I Journal of Biological Chemistry ·Palaniappan Kulanthaivel, Theresa Stewart, Mark A. Strege, T. Haryanto, Tim A. Smitka, Fitri Gusti Rahayu, Yasutaka Osada, A. C. Bannington, Kuo Ec, Eddie L. Angleton, DEBORAH L. MULLEN, Louis N. Jungheim, Valentine J. Klimkowski, Thalia I. Nicas, R. C. Thompson, Sheng-Bin Peng	2004	83
18	Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters Biochemical Pharmacology ·Anne H. Dantzig, Robert L. Shepard, Susan E. Pratt, Linda B. Tabas, Peter A. Lander, Liandong Ma, Donald C. Paul, Daniel C. Williams, Sheng-Bin Peng, Christopher A. Slapak, N Godinot, William L. Perry	2003	31
19	Identification and Characterization of Streptococcus pneumoniae Ffh, a Homologue of SRP54 Subunit of Mammalian Signal Recognition Particle Biochemical and Biophysical Research Communications ·Kuo Ec, 佐記子旭, Laura Campo, Martin Hénault, H L Watson, Hiroya Yamarin, Sheng-Bin Peng	2002	1
20	Development of an Internally Quenched Fluorescent Substrate and a Continuous Fluorimetric Assay for Streptococcus pneumoniae Signal Peptidase I Analytical Biochemistry ·Sheng-Bin Peng, Feng Zheng, Eddie L. Angleton, David L. Smiley, John Carpenter, J. E. Scott	2001	12

About Sheng-Bin Peng

Sheng-Bin Peng is a scholar working on Oncology, Immunology and Allergy, Immunology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 38 papers that have together received 1.7k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (9 papers), Chemokine receptors and signaling (9 papers), Immunotherapy and Immune Responses (7 papers), Colorectal Cancer Treatments and Studies (6 papers), Advanced Breast Cancer Therapies (5 papers), Peptidase Inhibition and Analysis (4 papers), Cancer-related Molecular Pathways (4 papers) and Cell Adhesion Molecules Research (3 papers). The work is most often cited by research in Oncology (852 citations), Immunology (358 citations), Molecular Biology (954 citations), Cancer Research (196 citations) and Immunology and Allergy (69 citations). Sheng-Bin Peng has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Shuguang Huang, Shuyu Li, Donald C. Paul, Sean G. Buchanan, Vipin Yadav, James J. Starling, Youyan Zhang, James R. Henry, Xueqian Gong and Jiangang Liu. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Molecular Cancer Therapeutics, Scientific Reports and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact